Payload Information
General Information of This Payload
| Payload ID | PAY0OSSQB |
|||||
|---|---|---|---|---|---|---|
| Name | STING agonist of TAK500 |
|||||
| Synonyms |
STING agonist of TAK500
Click to Show/Hide
|
|||||
| Target(s) | Stimulator of interferon genes protein (STING1) | |||||
| Structure |
|
|||||
| Formula | C30H31F2N9O11P2S2 |
|||||
| Isosmiles | CNCc1ccccc1C(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(S)O[C@@H]3[C@H](O)[C@@H](CO[P@@](=O)(S)O[C@H]2[C@H]1F)O[C@H]3n1cc(F)c2c(=O)[nH]cnc21 |
|||||
| InChI |
InChI=1S/C30H31F2N9O11P2S2/c1-33-6-13-4-2-3-5-14(13)27(43)39-24-20-26(36-10-34-24)41(12-38-20)29-19(32)22-17(50-29)9-48-54(46,56)52-23-21(42)16(8-47-53(45,55)51-22)49-30(23)40-7-15(31)18-25(40)35-11-37-28(18)44/h2-5,7,10-12,16-17,19,21-23,29-30,33,42H,6,8-9H2,1H3,(H,45,55)(H,46,56)(H,35,37,44)(H,34,36,39,43)/t16-,17-,19-,21-,22-,23-,29-,30-,53-,54-/m1/s1
|
|||||
| InChIKey |
ISJSBNLSDPJHRZ-ZQXNSGKOSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
857.708 |
Polar area |
245.16 |
||
Complexity |
857.1027745 |
xlogp Value |
3.0621 |
|||
Heavy Count |
56 |
Rot Bonds |
6 |
|||
Hbond acc |
18 |
Hbond Donor |
6 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
TAK-500 [Phase 1/2 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04879849 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, phase 1, dose-escalation study to evaluate the safety and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of non-small-cell lung cancer, triple-negative breast cancer, or squamous-cell carcinoma of the head and neck that has progressed on checkpoint inhibitors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04420884 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as a single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
|
||||
References